Evaluation of Povidone-Iodine in Pleurodesis of Malignant Pleural Effusion
Keywords:
pleurodesis, povidone-iodine, malignant pleural effusionAbstract
Background: Malignant pleural effusion (MPE) is a condition that malignant cells are presented in the pleural fluid. 10% povidone-iodine in pleurodesis is one of (MPE) treatment options.
This study aims to evaluate the safety, efficacy and the success rate of 10% povidone-iodine in pleurodesis procedure through thoracostomy by conducting; the assessment of radiological and clinical outcome after using of povidone –iodine as a chemical pleurodesis agent.
Randomized clinical trial, was carried out on 18 cases at Thoracic Surgery Department, Abuslem Trauma Center, Tripoli 2020 - 2021, all patients who underwent pleural drainge and received bedside mixture of 20 ml of 10% topical solution of povidone-iodine and 80 ml of normal saline, was Instilled into the pleural cavity through pleural catheter and then, the tube was clamped for 1 hour.
In the absence of excessive fluid drainage (> 250 mL/ day) and no fluid collection in chest x ray, the pleural catheter removed within 24-48 hours of sclerosant administration pleurodesis with 10% povidone-iodine. After pleurodesis, all patients were assessed via chest X-ray (CXR) after procedure, and at one month.
Data collected throughout history, basic clinical examination, laboratory investigations and outcome measures coded, entered and analyzed using Microsoft Excel software.
Results: revealed that early response was 72.2% complete, partial in 16.6%, and failure 11.1%, major complication was nausea.
We concluded that povidone-iodine is a safe and effective agent with minor side effects in pleurodesis and treatment of MPE and proposed povidone-iodine as a proper, accessible, and low-cost alternative sclerosing agent.
References
AeLony HY, King R and Boiitin C (1991): Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann. Intern. Med; 115: 778-82.
Agarwal, R; Khan, A; Aggarwal, AN; et al. (2012): Efficacy and safety of iodopovidone pleurodesis: a systematic review and meta-analysis. The Indian Journal of Medical Research; 135: 297–304.
Agostoni E, and Zocchi L (1998): Mechanical coupling and liquid exchanges in the pleural space. Clin Chest Med; 19 (2): 24l-261.
Andrade-Neto JD, Oliveira SFQ, Vianna SP, et al. (2010): Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology; 15: 115–118.
Antony VB, Nasreen N, Mohammed KA, et al. (2004): Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest;126:1522-8.
Antunes G, Neville E, Duffy J, Ali N (2003): BTS Guidelines for the management of malignant pleural effusions. Thorax; 58:ii29-ii38.
Arfa, M. A. (2014). Comparative study of pleurodesis using iodopovidone and bleomycin in management of malignant pleural effusion, (july).
Benkelman CJ, van den Berg AJ, Moekstra MJ, et al. (2008): Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns; 34: 845-855.
Brega-Massone P, Conti B, Magnani B, et al. (2004): Minimally invasive thoracic surgery for diagnostic assessment and palliative treatment in recurrent neoplastic pleural effusion. Thorac Cardiovasc Surg; 52: 191–195.
British Medical Association (2015): British national formulary: BNF; 69 (ed.): 840.
Broaddus VC (2008): Transudative pleural effusions. In: Loddenkemper R, Antony VB, ed. Pleural Diseases (European Respiratory Monograph, Vol 7, Monograph 22), Sheffield, UK: European Respiratory Society Journals: 157-176.
Bydder S, Phillips M, Joseph DJ, et al. (2004): A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer; 91:9-10.
Caglayan B, Torun E, Turan D, et al. (2008): Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Ann Surg Oncol; 15:2594-9.
Caldwell, J., Edriss, H., & Nugent, K. (2018, July). Chronic peritoneal indwelling catheters for the management of malignant and nonmalignant ascites. In Baylor University Medical Center Proceedings (Vol. 31, No. 3, pp. 297-302). Taylor & Francis.
Chakrabarti B, Ryland I, Sheard J, et al. (2006): The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest; 129(6): 1549-1555.
Charpidou A., Harrington KJ, Syrigos KN (2006): Management of Malignant Pleural Effusions. In: Syrigos KS., Nutting CM, Roussos C. (eds.) Tumors of the Chest Biology, Diagnosis and Management. Berlin: Springer; 563-573.
Chen H, Brahmer J. Management of malignant pleural effusion. Curr Oncol Rep 2008;10:287-93.
Dias, J., Neto, A., Terra, M., Teixeira, M., Vianna, S., & Manuel, P. (2015). Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion, 225, 369–375. https://doi.org/10.1159/000440727.
Dixit, R., Agarwal, K. C., Gokhroo, A., Patil, C. B., Meena, M., Shah, N. S., & Arora, P. (2017). Diagnosis and management options in malignant pleural effusions. Lung India: official organ of Indian Chest Society, 34(2), 160.
Dresler CM, Olak J, Herndon JE 2nd, et al. (2005): Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest; 127(3):909-15.
Dumville, JC; McFarlane, E; Edwards, P; et al. (2015): Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. The Cochrane Database of Systematic Reviews; 4: CD003949.
Duysinx B, Nguyen D, Louis R, et al. (2004): Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest; 125:489-93.
Ellington MJ, Reuter S, Harris SR, et al. (2015): Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents; 45: 477-484.
Garza-Gangemi, A. M., Barquet-Muñoz, S. A., Villarreal-Colín, S. P., Medina-Franco, H., Cortés-González, R., Vilar-Compte, D., & Cantú-de-León, D. (2016). Randomized Phase II Study of Talc Versus Iodopovidone for the Prevention of Seroma Formation Following Modified Radical Mastectomy. Revista de Investigación Clínica, 67(6), 357-365.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Amhamed Ahmed Alhajaji، Ali Giuma Elmarghni
This work is licensed under a Creative Commons Attribution 4.0 International License.